Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The investigators primary aim is to increase chemotherapeutic drug uptake in inoperable
tumours
The specific sub-objectives of the studies are:
- To quantify tumour sizes and relate it to the patient survival over time, dependent of
treatment method.
- To evaluate and compare the toxic effects and safety of gemcitabine in combination with
US contrast agent under sonication with gemcitabine alone.
- Develop and validate new ultrasound perfusion algorithms based on burst- replenishment
for diagnosis and monitoring of therapy.
- To quantify gemcitabine and its main metabolites in plasma and in circulating
mononuclear cells before, during and after pancreatic sonication, and to quantify the
concentration of intracellular endogenous nucleotides in circulating mononuclear cells
at the same time points.
- To assess plasma and tissue concentrations of gemcitabine, its main metabolites and
endogenous nucleotides in those patients where surgical resection can be performed on
standard clinical indications.